相关实验视频

Updated: Jun 16, 2025

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

利拉格卢提德通过Myo1c/Dock5促进糖尿病伤口愈合

Qian Zhang^1,2,3, Chunlin Zhang^1,2, Changjiang Kang^2,4

¹School of Life Sciences, Chongqing University, Chongqing, 401331, China.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

|August 19, 2024

概括

利拉格卢提德通过通过Myo1c和Dock5相互作用增强角质细胞功能,加速糖尿病伤口愈合. 这些发现表明,利拉格卢提德作为糖尿病伤口病理的潜在治疗方法.

科学领域:

生物医学科学生物医学科学
分子生物学分子生物学
伤口治愈研究研究伤口治愈研究

背景情况:

由于细胞功能受损,糖尿病伤口存在重大临床挑战.
目前的治疗方法缺乏针对糖尿病伤口并发症的指南推的低血糖药物.
了解糖尿病中伤口愈合的分子机制至关重要.

研究的目的:

调查利拉格卢提德在加速糖尿病伤口关闭方面的疗效.
阐明利拉格卢提德对角质细胞作用的潜在分子机制.
为了确定关键的蛋白质相互作用,涉及到liraglutide介导的伤口愈合.

主要方法:

使用的糖尿病小鼠模型 (db/db和链毒素诱导).
评估了伤口关闭,再上皮化和原沉积.
采用了状细胞特异性淘汰赛小鼠模型 (细胞动力学标记5 - Dock5).
研究的蛋白质相互作用包括非传统的肌肉蛋白1c (Myo1c) 和Dock5.5.

主要成果:

利拉格卢提德在糖尿病小鼠中显著加快了伤口的关闭.
利拉格卢提德增强了角质细胞的增殖,迁移和粘附.
治愈效果取决于Dock5,在淘汰模式中取消.
利拉格卢提德稳定了Myo1c,增强了Myo1c/Dock5的相互作用.

结论:

利拉格卢提德通过稳定Myo1c和增强Myo1c/Dock5相互作用促进糖尿病伤口愈合.
这种机制涉及liraglutide直接结合Myo1c在阿金93.3.
利拉格卢提德显示出作为糖尿病伤口病理学的有效治疗剂的潜力.

关键词:

在5号码头.糖尿病患者的伤口愈合角质细胞的功能是角质细胞.利拉格卢提德 (liraglutide) 是一种葡萄糖类药物.

更多相关视频

Doxycycline Loaded Collagen-Chitosan Composite Scaffold for the Accelerated Healing of Diabetic Wounds

Doxycycline Loaded Collagen-Chitosan Composite Scaffold for the Accelerated Healing of Diabetic Wounds

Published on: August 21, 2021

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers

Published on: March 3, 2023

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...